Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2010-019992-30
    Sponsor's Protocol Code Number:CC-10004-PSOR-009
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2010-11-17
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2010-019992-30
    A.3Full title of the trial
    Estudio fase III, multicéntrico, randomizado, doble ciego, controlado con placebo, de eficacia y seguridad de Apremilast (CC-10004) en pacientes con psoriasis en placas moderada o severa. A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis
    A.4.1Sponsor's protocol code numberCC-10004-PSOR-009
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCelgene Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameApremilast
    D.3.2Product code CC-10004
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNApremilast
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameApremilast
    D.3.2Product code CC-10004
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNApremilast
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameApremilast
    D.3.2Product code CC-10004
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNApremilast
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 3
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Psoriasis, una enfermedad crónica inflamatoria de la piel, se calcula que afecta hasta el 2,5% de la población mundial. La psoriasis en placas es la forma más común de esta enfermedad.”

    Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's
    population. Plaque-type psoriasis is the most common form of this disease.
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 12.1
    E.1.2Level LLT
    E.1.2Classification code 10037153
    E.1.2Term Psoriasis
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluar la eficacia clínica de Apremilast 30 mg BID en comparación con placebo, en sujetos con psoriasis en placas entre moderada y grave.
    E.2.2Secondary objectives of the trial
    –Evaluar la seguridad y tolerabilidad de Apremilast 30 mg BID, en comparación con placebo, en sujetos con psoriasis en placas de moderada a grave.
    –Evaluar el efecto de Apremilast 30 mg BID en comparación con placebo sobre la calidad de vida
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Hombres o mujeres >= 18 años en el momento de firmar el documento de consentimiento informado
    2.Comprender y firmar voluntariamente el documento de consentimiento informado antes de someterse a cualquier evaluación/procedimiento relacionado con el estudio
    3.Ser capaz de cumplir con el programa de visitas del estudio y demás requisitos del protocolo
    4.Diagnóstico de psoriasis en placas crónica durante por lo menos 12 meses antes de la selección
    5.Tener psoriasis en placas entre moderada y grave en la selección e inicio definida como:a.puntuación PASI >= 12 y b.BSA>= 10%, y c.sPGA >= 3 (moderada).
    6.Debe ser candidato para fototerapia y/o terapia sistémica
    7.Debe tener buena salud (excepto por la psoriasis) según estimación del investigador, basándose en el historial médico, la exploración física, el ECG de 12 derivaciones, los análisis de laboratorios clínicos y el análisis de orina.
    8-Debe cumplir los siguientes criterios de laboratorio a. Recuento de leucocitos>=3.000/mm3 (>= 3,0 x 10^9/l) y < 14.000/mm3 (< 14 x 10^9/l)b. Recuento de plaquetas >= 100.000/microl (>= 100 x 10^9/l)c.Creatinina sérica <= 1,5 mg/dl (<= 132,6 micromol/l)d.AST (SGOT) y ALT (SGPT) <=2 x límite superior de lo normal (ULN),e.Bilirrubina total <= 2 mg/dl (34micromol/l)f.Hemoglobina >= 9 g/dl (>= 5,6 mmol/l),g. Hemoglobina A1c <= 9,0 %.
    9.Las mujeres en edad fértil (FCBP) deben presentar una prueba de embarazo negativa en la selección e inicio. Las FCBP que mantengan relaciones con probabilidades de concepción, si es posible, deberán usar 2 formas de anticonceptivos mientras tomen la medicación del estudio y durante 28 días por lo menos después de tomar la última dosis de la medicación del estudio: una forma de de alta efectividad (p.e. hormonal, dispositivo intrauterino [DIU], ligadura de trompas, vasectomía de la pareja) y una forma adicional (condón de látex o cualquier condón de otro material que NO esté hecho de membrana natural [animal] [p.e. poliuretano], diafragma, esponja). Si no es posible emplear una forma de anticonceptivo de alta efectividad, se deberán emplear 2 formas de barrera anticonceptiva, como condón de látex o cualquier condón de otro material que NO esté hecho de membrana natural (animal) (por ej. poliuretano) con cualquiera de los siguientes: esponja con espermicida o diafragma con espermicida.
    10.Los sujetos varones (incluyendo aquellos con vasectomía) que mantengan relaciones en la que sea posible la concepción deberán emplear una barrera anticonceptiva, como condón de látex o cualquier condón de otro material que NO esté hecho de membrana natural (animal) (p.e. poliuretano) mientras que estén tomando la medicación del estudio y durante por lo menos 28 días después de la última dosis de la medicación del estudio.
    E.4Principal exclusion criteria
    1- A parte de la psoriasis, historial de cualquier enfermedad clínicamente significativa (a juicio del investigador) de tipo cardiaco, endocrino, pulmonar, neurológico, psiquiátrico, hepático, renal, hematológico, inmunológico o cualquier otra enfermedad grave no controlada.
    2.Cualquier afección, incluyendo la presencia de anormalidades de laboratorio, que pudiera poner al sujeto en un nivel de riesgo inaceptable por su participación en el estudio.
    3.Toda afección que interfiera con la capacidad de interpretación de datos del estudio.
    4.Embarazo o lactancia
    5.Historial de alergia a cualquier componente del PI
    6.Antígeno de superficie de hepatitis B positivo en la selección
    7.Anticuerpo anti-hepatitis C positivo en la Selección
    8.AST (SGOT) y/o ALT (SGPT) > 1,5 X ULN y bilirrubina total > ULN y/o albúmina < LLN
    9.Tuberculosis activa (TB) o historial de tratamiento incompleto de TB
    10.Anormalidad clínicamente significativa en la ECG de 12 derivaciones en la selección
    11.Anormalidad clínicamente significativa basada en radiografía torácica con por lo menos vista PA (la radiografía se debe realizar en las 12 semanas anteriores a la selección o durante la visita de selección). Es muy recomendable una vista lateral adicional, aunque no es obligatoria.
    12.Historial de virus de la inmunodeficiencia humana (VIH), o tener inmunodeficiencia congénita o adquirida (p.e. enfermedad de inmunodeficiencia variable común)
    13.Abuso presente de sustancias o historial de abuso de sustancias en los 6 meses anteriores a la selección
    14.Infecciones bacterianas que requieran tratamiento con antibióticos orales o inyectables, o infecciones víricas o fúngicas significativas en las 4 semanas previas a la selección. Todo tratamiento de esas infecciones deberá haber sido completado por lo menos 4 semanas antes de la selección.
    15.Tumor o historial de tumores (excepto para carcinoma de células basales tratado [ curado] o carcinoma escamocelular in situ y neoplasia intraepitelial cervical [CIN] tratada [ curada] o carcinoma in situ de cérvix)
    16.Brote o rebote de psoriasis en las 4 semanas anteriores a la selección
    17.Pruebas de trastornos cutáneos que podrían interferir con las evaluaciones clínicas
    18.Tratamiento tópico dentro de las 2 semanas desde la aleatorización (incluyendo entre otros corticosteroides tópicos, retinoides tópicos o preparados de análogos de vitamina D, tacrolimus, pimecrolimus o antralin/ditranol). Excepciones: se permitirán corticosteroides de baja potencia (clase 6 ó 7; consulte el MI) como terapia de base para el tto. de rostro, axilas e ingles de acuerdo con el uso recomendado por el fabricante durante el curso del estudio. Los sujetos con psoriasis en el cuero cabelludo podrán utilizar champú de alquitrán y/o ácido salicílico en sus lesiones. También se permitirá una crema hidratante no medicamentosa (p.e. Eucerin®) para las lesiones corporales solamente. Los sujetos no deberán usar estos tratamientos tópicos en las 24 horas anteriores a la visita clínica.
    19.Terapia sistémica para psoriasis en las 4 semanas anteriores a la aleatorización (incluyendo entre otras ciclosporina, corticosteroides, metotrexato, retinoides orales, micofenolato, tioguanina, hidroxiurea, sirolimus, sulfasalazina, azatioprina, ésteres de ácido fumárico)
    20.Uso de fototerapia en las 4 semanas anteriores a la aleatorización (es decir, UVB, PUVA)
    21.Adalimumab, etanercept, infliximab o certolizumab pegol en las 12 semanas anteriores a la aleatorización
    22. Alefacept, briakinumab o ustekinumab en las 24 semanas anteriores a la aleatorización
    23.Uso de cualquier fármaco de investigación en las 4 semanas anteriores a la aleatorización, o 5 semividas farmacocinéticas/farmacodinámicas, si se conoce (lo que resulte más largo)
    24.Exposición solar prolongada o uso de cabinas de bronceado u otras fuentes de luz ultravioleta (UV)
    25.Tratamiento anterior con Apremilast
    E.5 End points
    E.5.1Primary end point(s)
    Proporción de sujetos tratados con Apremilast 30 mg BID o placebo que logran por lo menos una reducción del 75% en PASI (PASI-75) en la Semana 16 respecto al inicio del estudio.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA17
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Refiérase al protocolo
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state42
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 180
    F.4.2.2In the whole clinical trial 405
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    see protocol
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2011-01-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2010-12-10
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2016-11-30
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 02:53:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA